GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Antibody
Comment: Adimanebart is an anti-muscle associated receptor tyrosine kinase (MuSK) monoclonal antibody with agonist action. It was designed to treat neuromuscular diseases, by improving impaired function at the neuromuscular junction in patients with conditions that are characterised by fatigable muscle weakness, such as congenital myasthenia, myasthenia gravis and ALS. The goal of this approach is to reduce muscle weakness and fatigability. This may be the INN for argenx's clinical candidate ARGX-119 [1].
|
| References |
|
1. Vanhauwaert R, Oury J, Vankerckhoven B, Steyaert C, Jensen SM, Vergoossen DLE, Kneip C, Santana L, Lim JL, Plomp JJ et al.. (2024)
ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome. Sci Transl Med, 16 (765): eado7189. [PMID:39292800] |
